Depomed, Inc.



$8.17Share Price
$515 MMarket Cap
0.4%EBIT / EV
6.3%FCF / EV
8.4%Cash ROIC
70.6%3yr Avg Revenue Growth
0.83Current Ratio
star logo

Business Model Diligence

We do not yet have Business Model Diligence for this stock.

Statistical Diligence

x mark The EBIT / Enterprise Value of 0.4% ranks as Poor.
check mark The Free Cash Flow / Enterprise Value of 6.3% ranks as Above Average.
x mark The Return on Invested Capital Value of 0.6% ranks as Poor.
check mark The Cash Return on Capital Value of 8.4% ranks as Average.
check mark The 3 Year Average Revenue Growth Value of 70.6% ranks as Very High.
x mark Near-term Financial Health appears to be Worrisome. The Current Ratio is 0.83.

Company Description

Depomed, Inc. is a pharmaceutical company, which manufactures and distributes pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.


You must have a MagicDiligence Membership to view the Calculations for this stock. If you are already a member, you need to log in first.